Anteris Technologies has recently announced the launch of its initial public offering in the U.S. The company plans to raise funds through this IPO to further advance the development of its DurAVR transcatheter heart valve technology. The IPO consists of 14.8 million shares of common stock, with an additional 2.22 million shares available to underwriters under a 30-day option. Anteris has applied to list its shares on the Nasdaq Global Market under the AVR ticker.
The primary focus of the funds raised will be to support the development of the DurAVR transcatheter heart valve and to begin a global pivotal study targeting severe aortic stenosis treatment. Any leftover funds will be used for working capital, corporate purposes, and repaying convertible note facility obligations.
The DurAVR is a transcatheter heart valve designed by Anteris to treat aortic stenosis, using a single piece of bioengineered tissue. The valve is made using Anteris’ patented anti-calcification tissue technology, Adapt Tissue, which has been used clinically for over 10 years and distributed to over 55,000 patients worldwide. The heart valve is delivered through the ComASUR Delivery System, which allows for controlled deployment and accurate placement with balloon-expandable delivery, ensuring precise alignment with the heart’s native commissures for ideal valve positioning.
Anteris Technologies’ IPO marks a significant step forward in the development of its innovative heart valve technology, with the potential to revolutionize treatment for aortic stenosis patients worldwide.
Source
Photo credit www.massdevice.com